152 filings
Page 2 of 8
6-K
tss4zrgii 0ww
14 Dec 23
Report of Foreign Private Issuer
9:41am
424B3
bo5x99lyuv0
5 Dec 23
Prospectus supplement
3:15pm
424B3
xz5meu7qlzs9q
5 Dec 23
Prospectus supplement
3:00pm
6-K
8qhw05crxuy ecvea2
5 Dec 23
Report of Foreign Private Issuer
8:01am
EFFECT
h5e 6qq5fe5sitzxj
5 Dec 23
Notice of effectiveness
12:15am
POS AM
10h8zj mqb5z
4 Dec 23
Prospectus update (post-effective amendment)
6:17am
CORRESP
5ttmw flt
4 Dec 23
Correspondence with SEC
12:00am
6-K
x8h 63qw8msa
28 Nov 23
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
9:00am
POS AM
tno4pgnw9jumx9tuzo
21 Nov 23
Prospectus update (post-effective amendment)
10:36am
6-K
i3gucwitcbix1hxpz
13 Nov 23
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
9:28am
6-K
nrghhsqxha4nlv45wmg
6 Nov 23
Report of Foreign Private Issuer
8:35am
6-K
q7c781wyrushn3fsw
17 Oct 23
NeuroSense CEO Provides Q3 2023 Update
8:45am
6-K
7v4py9 co6vl8k
4 Oct 23
Report of Foreign Private Issuer
9:12am
6-K
zrwl488d2fua
2 Oct 23
Report of Foreign Private Issuer
11:39am
6-K
42az4r6l3 6h4ezlps
29 Sep 23
Report of Foreign Private Issuer
5:15pm
6-K
gurv 3k5mhkec0x8u
20 Sep 23
Report of Foreign Private Issuer
9:16am
6-K
wgg3pe2shp1ghzc5o8rh
19 Sep 23
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
9:15am
6-K
ugljvu mplv1
12 Sep 23
Report of Foreign Private Issuer
9:20am
424B3
hz19pt6t1w1ngoii
7 Sep 23
Prospectus supplement
4:31pm
EFFECT
o8llnidoc1l2lvh y3b
6 Sep 23
Notice of effectiveness
12:15am